Article
Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment: the genetics of hypertension associated treatment study.
Stroke - 1 Feb 2011
Sherva Richard, Ford Charles E, Eckfeldt John H, Davis Barry R, Boerwinkle Eric, Arnett Donna K
Abstract excerpt
BACKGROUND AND PURPOSE: Atherothrombotic diseases including stroke share a common etiology of atherosclerosis, and susceptibility to atherosclerosis has a genetic component. Stromelysin-1 (matrix metalloproteinase-3 [MMP3]) regulates arterial matrix composition and is a candidate gene for atherothrombosis. A common polymorphism of MMP3 alters expression levels and affects atherosclerotic progression and plaque...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.